 = Discovery stage. (24.37%, 2023)
|
 = Translation stage. (39.50%, 2023)
|
 = Clinically available. (36.13%, 2023)
|
|
|
| Description | Y/N | Source |
| Grants | yes | NIH R01 AI123820-01 |
| Salary | no | |
| Board Member | no | |
| Stock | no | |
| Expenses | yes | University of Victoria |
| IP Royalty | no |
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |